Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGEN Compugen	$1.45 -2.0%	$1.60	$1.13 ▼ $2.66	$132.07M	2.61	265,927 shs	96,988 shs
MCRB Seres Therapeutics	$16.86 +5.6%	$11.74	$6.53 ▼ $26.40	$139.81M	2.9	126,564 shs	208,903 shs
PLX Protalix BioTherapeutics	$1.52 -5.6%	$1.49	$0.89 ▼ $3.10	$121.00M	-0.21	847,167 shs	933,668 shs
SCYX SCYNEXIS	$0.80 -5.1%	$0.76	$0.66 ▼ $1.79	$32.98M	1.64	204,563 shs	137,084 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGEN Compugen	-2.03%	+0.69%	-8.23%	+4.32%	-17.14%
MCRB Seres Therapeutics	+5.57%	+10.27%	+14.93%	+126.01%	-6.65%
PLX Protalix BioTherapeutics	-5.59%	+0.66%	+10.14%	-8.98%	+63.44%
SCYX SCYNEXIS	-5.15%	-8.39%	+5.47%	+1.47%	-51.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGEN Compugen	1.9471 of 5 stars	3.5	4.0	0.0	1.8	0.0	0.0
MCRB Seres Therapeutics	3.0713 of 5 stars	2.9	1.0	4.6	2.0	0.8	0.0
PLX Protalix BioTherapeutics	3.6465 of 5 stars	3.5	3.0	0.0	3.4	1.7	1.9
SCYX SCYNEXIS	0.9725 of 5 stars	0.0	4.0	0.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGEN Compugen	3.00	Buy	$4.00	175.86% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	336.93% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	886.84% Upside
SCYX SCYNEXIS	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGEN Compugen	$27.86M	4.64	N/A	N/A	$0.56 per share	2.59
MCRB Seres Therapeutics	$126.32M	1.17	N/A	N/A	$3.76 per share	4.48
PLX Protalix BioTherapeutics	$59.76M	2.02	$0.09 per share	17.80	$0.47 per share	3.23
SCYX SCYNEXIS	$2.63M	11.89	N/A	N/A	$1.45 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGEN Compugen	-$14.23M	-$0.22	N/A	N/A	N/A	-87.45%	-34.77%	-16.82%	N/A
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-350.16%	-67.69%	N/A
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.90	N/A	-21.03%	-30.89%	-11.74%	N/A
SCYX SCYNEXIS	-$21.29M	-$0.40	N/A	16.03	N/A	-599.05%	-41.02%	-26.14%	8/14/2025 (Estimated)

Latest SCYX, CGEN, PLX, and MCRB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	SCYX SCYNEXIS	-$0.23	-$0.14	+$0.09	-$0.14	$0.15 million	$1.36 million
8/6/2025	Q2 2025	CGEN Compugen	-$0.07	-$0.08	-$0.01	-$0.08	$3.95 million	$1.26 million
8/6/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	-$2.27	+$0.45	-$2.27	$11.75 million	N/A
5/19/2025	Q1 2025	CGEN Compugen	-$0.06	-$0.08	-$0.02	-$0.08	$3.70 million	$2.28 million
5/15/2025	Q1 2025	SCYX SCYNEXIS	-$0.23	-$0.17	+$0.06	-$0.11	$0.14 million	$0.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGEN Compugen	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGEN Compugen	N/A	4.74	4.74
MCRB Seres Therapeutics	N/A	1.57	1.57
PLX Protalix BioTherapeutics	N/A	1.98	1.27
SCYX SCYNEXIS	N/A	5.83	5.83

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGEN Compugen	12.22%
MCRB Seres Therapeutics	59.34%
PLX Protalix BioTherapeutics	16.53%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
CGEN Compugen	9.50%
MCRB Seres Therapeutics	4.70%
PLX Protalix BioTherapeutics	6.50%
SCYX SCYNEXIS	4.86%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGEN Compugen	70	89.24 million	80.76 million	Optionable
MCRB Seres Therapeutics	330	8.75 million	8.34 million	Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
SCYX SCYNEXIS	60	39.02 million	37.12 million	Optionable

SCYX, CGEN, PLX, and MCRB Headlines

Recent News About These Companies

Scynexis reports Q2 EPS (14c), consensus (19c)

August 14 at 9:17 AM | msn.com

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14 at 9:17 AM | finanznachrichten.de

SCYNEXIS Reports Improved Financials Amidst Strategic Developments

August 14 at 9:17 AM | msn.com

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 13 at 4:30 PM | globenewswire.com

SCYNEXIS (SCYX) to Release Quarterly Earnings on Thursday

August 13 at 2:50 AM | americanbankingnews.com

SCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis Treatment

August 8, 2025 | msn.com

SCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSK

May 30, 2025 | nasdaq.com

SCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA Hold

May 28, 2025 | insidermonkey.com

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

May 28, 2025 | globenewswire.com

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025 | finance.yahoo.com

Scynexis to present preclinical data on SCY-247 at ESCMID Meeting

April 9, 2025 | markets.businessinsider.com

SCYNEXIS Full Year 2024 Earnings: Misses Expectations

March 14, 2025 | finance.yahoo.com

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | markets.businessinsider.com

SCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study Restart

March 12, 2025 | quiverquant.comQ

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

March 12, 2025 | globenewswire.com

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

December 18, 2024 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)

December 5, 2024 | markets.businessinsider.com

SCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy Rating

November 9, 2024 | markets.businessinsider.com

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 6, 2024 | globenewswire.com

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years

October 30, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCYX, CGEN, PLX, and MCRB Company Descriptions

Compugen NASDAQ:CGEN

$1.45 -0.03 (-2.03%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.44 0.00 (-0.34%)

As of 08/14/2025 04:47 PM Eastern

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

Seres Therapeutics NASDAQ:MCRB

$16.86 +0.89 (+5.57%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$17.09 +0.23 (+1.36%)

As of 08/14/2025 07:57 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Protalix BioTherapeutics NYSE:PLX

$1.52 -0.09 (-5.59%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.56 +0.03 (+2.30%)

As of 08/14/2025 07:44 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

SCYNEXIS NASDAQ:SCYX

$0.80 -0.04 (-5.15%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.81 +0.01 (+1.42%)

As of 08/14/2025 07:31 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time